Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
191 hedge funds and large institutions have $2.06B invested in Akero Therapeutics in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 65 increasing their positions, 50 reducing their positions, and 18 closing their positions.
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
30% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 50
14% more funds holding
Funds holding: 168 → 191 (+23)
1.13% more ownership
Funds ownership: 105.14% → 106.28% (+1.1%)
5% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $16.3M
1% less capital invested
Capital invested by funds: $2.09B → $2.06B (-$30.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.5M |
| 2 |
RI
RTW Investments
New York
|
+$28.5M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$24.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$19.7M |
| 5 |
SG Americas Securities
New York
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$47.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$31.6M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$19.1M |
| 4 |
PA
Perceptive Advisors
New York
|
-$16M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.7M |
AKRO Hedge Fund Activity: Q4 2024 in Review
191 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2024, worth a combined $2.06B — down 1.5% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AKRO positions and 18 closed out — a net gain of 23 holders — while 65 added to existing stakes and 50 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.5M. The largest seller was Alkeon Capital Management, cutting an estimated $47.4M.
- 191 institutional investors held Akero Therapeutics (AKRO) as of Q4 2024, up from 168 in Q3 2024.
- Funds reported $2.06B of Akero Therapeutics stock for Q4 2024, down 1.5% quarter-over-quarter.
- 41 funds opened new Akero Therapeutics positions in Q4 2024 and 18 closed out, a net change of +23 holders.
- The largest Akero Therapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $36.5M added.
- The largest Akero Therapeutics seller in Q4 2024 was Alkeon Capital Management, an estimated $47.4M sold.
Based on aggregated 13F filings for Q4 2024.